{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:26:11Z","timestamp":1787660771432,"version":"build-2736575974"},"reference-count":187,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41575-026-01219-3","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:53:26Z","timestamp":1781513606000},"page":"722-736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Steatotic liver disease in Latin America: current views and perspectives"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5607-0698","authenticated-orcid":false,"given":"Francisco","family":"Idalsoaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-4930","authenticated-orcid":false,"given":"Luis Antonio","family":"D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5334-1528","authenticated-orcid":false,"given":"Francisco","family":"Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3590-2472","authenticated-orcid":false,"given":"Adrian","family":"Gadano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2848-417X","authenticated-orcid":false,"given":"Claudia P.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-396X","authenticated-orcid":false,"given":"Juan Pablo","family":"Arab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0499-4191","authenticated-orcid":false,"given":"Marco","family":"Arrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"1219_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","volume":"404","author":"M Israelsen","year":"2024","unstructured":"Israelsen, M., Francque, S., Tsochatzis, E. A. & Krag, A. Steatotic liver disease. Lancet 404, 1761\u20131778 (2024).","journal-title":"Lancet"},{"key":"1219_CR2","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2024","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann. Hepatol. 29, 101133 (2024).","journal-title":"Ann. Hepatol."},{"key":"1219_CR3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/HEP.0000000000000674","volume":"82","author":"MQ Khan","year":"2025","unstructured":"Khan, M. Q., Hassan, S., Lizaola-Mayo, B. C., Bhat, M. & Watt, K. D. Navigating the \u2018specific etiology\u2019 steatohepatitis category: evaluation and management of nonalcohol\/nonmetabolic dysfunction-associated steatohepatitis. Hepatology 82, 504\u2013521 (2025).","journal-title":"Hepatology"},{"key":"1219_CR4","doi-asserted-by":"publisher","first-page":"e70017","DOI":"10.1111\/liv.70017","volume":"45","author":"G Ayares","year":"2025","unstructured":"Ayares, G. et al. MetALD: new perspectives on an old overlooked disease. Liver Int. 45, e70017 (2025).","journal-title":"Liver Int."},{"key":"1219_CR5","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","volume":"80","author":"V Ratziu","year":"2024","unstructured":"Ratziu, V., Boursier, J. & AFEF Group for the Study of Liver Fibrosis. Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD. J. Hepatol. 80, e51\u2013e52 (2024).","journal-title":"J. Hepatol."},{"key":"1219_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jhep.2024.11.028","volume":"82","author":"JP Arab","year":"2025","unstructured":"Arab, J. P. et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. J. Hepatol. 82, 744\u2013756 (2025).","journal-title":"J. Hepatol."},{"key":"1219_CR7","unstructured":"World Bank. Latin America & Caribbean data. World Bank https:\/\/data.worldbank.org\/region\/latin-america-and-caribbean (2026)."},{"key":"1219_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11938-022-00382-1","volume":"20","author":"LA D\u00edaz","year":"2022","unstructured":"D\u00edaz, L. A. et al. Liver diseases in Latin America: current status, unmet needs, and opportunities for improvement. Curr. Treat. Options Gastroenterol. 20, 261\u2013278 (2022).","journal-title":"Curr. Treat. Options Gastroenterol."},{"key":"1219_CR9","doi-asserted-by":"publisher","first-page":"101175","DOI":"10.1016\/j.aohep.2023.101175","volume":"29","author":"LA D\u00edaz","year":"2024","unstructured":"D\u00edaz, L. A., Villota-Rivas, M., Barrera, F., Lazarus, J. V. & Arrese, M. The burden of liver disease in Latin America. Ann. Hepatol. 29, 101175 (2024).","journal-title":"Ann. Hepatol."},{"key":"1219_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.gastha.2021.12.011","volume":"1","author":"J Ruiz-Manriquez","year":"2022","unstructured":"Ruiz-Manriquez, J. et al. Prevalence of metabolic-associated fatty liver disease in Mexico and development of a screening tool: the MAFLD-S score. Gastro. Hep. Adv. 1, 352\u2013358 (2022).","journal-title":"Gastro. Hep. Adv."},{"key":"1219_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/cld.759","volume":"13","author":"C Pinto Marques Souza de Oliveira","year":"2019","unstructured":"Pinto Marques Souza de Oliveira, C., Pinchemel Cotrim, H. & Arrese, M. Nonalcoholic fatty liver disease risk factors in Latin American populations: current scenario and perspectives. Clin. Liver Dis. 13, 39\u201342 (2019).","journal-title":"Clin. Liver Dis."},{"key":"1219_CR12","doi-asserted-by":"publisher","first-page":"102495","DOI":"10.1016\/j.jceh.2024.102495","volume":"15","author":"M Souza","year":"2025","unstructured":"Souza, M., Al-Sharif, L., Diaz, I., Mantovani, A. & Villela-Nogueira, C. A. Global epidemiology and implications of PNPLA3 I148M variant in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. J. Clin. Exp. Hepatol. 15, 102495 (2025).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"1219_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2025.04.035","volume":"83","author":"LA D\u00edaz","year":"2025","unstructured":"D\u00edaz, L. A. et al. High inherited risk predicts age-associated increases in fibrosis in patients with MASLD. J. Hepatol.\u00a083,\u00a0849\u2013859\u00a0(2025).","journal-title":"J. Hepatol."},{"key":"1219_CR14","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.cgh.2025.02.006","volume":"23","author":"GJ Kit Ho","year":"2025","unstructured":"Kit Ho, G. J. et al. High global prevalence of steatotic liver disease and associated subtypes: a meta-analysis. Clin. Gastroenterol. Hepatol.\u00a023,\u00a02423\u20132432.e1\u00a0(2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1219_CR15","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/ueg2.70072","volume":"13","author":"P Danpanichkul","year":"2025","unstructured":"Danpanichkul, P. et al. The rising Global Burden of MASLD and other metabolic diseases (2000\u20132021). United European\u00a0Gastroenterol. J. 13, 1141\u20131154\u00a0(2025).","journal-title":"United European\u00a0Gastroenterol. J."},{"key":"1219_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3350\/cmh.2024.0835","volume":"31","author":"P Danpanichkul","year":"2025","unstructured":"Danpanichkul, P. et al. Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021. Clin. Mol. Hepatol. 31, 525\u2013547 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"1219_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s43856-024-00649-x","volume":"4","author":"LA D\u00edaz","year":"2024","unstructured":"D\u00edaz, L. A. et al. Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria. Commun. Med. 4, 219 (2024).","journal-title":"Commun. Med."},{"key":"1219_CR18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77, 1335\u20131347 (2023).","journal-title":"Hepatology"},{"key":"1219_CR19","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jamainternmed.2025.4769","volume":"185","author":"NA Cumpian","year":"2025","unstructured":"Cumpian, N. A., Gutierrez, J. A., Wu, W. & Saab, S. Targeting MASLD and MASH in the US Hispanic\/Latino population: a review. JAMA Intern. Med. 185, 1376\u20131386 (2025).","journal-title":"JAMA Intern. Med."},{"key":"1219_CR20","doi-asserted-by":"publisher","first-page":"e0133","DOI":"10.1097\/HC9.0000000000000133","volume":"7","author":"S Amonker","year":"2023","unstructured":"Amonker, S., Houshmand, A., Hinkson, A., Rowe, I. & Parker, R. Prevalence of alcohol-associated liver disease: a systematic review and meta-analysis. Hepatol. Commun. 7, e0133 (2023).","journal-title":"Hepatol. Commun."},{"key":"1219_CR21","doi-asserted-by":"publisher","first-page":"156101","DOI":"10.1016\/j.metabol.2024.156101","volume":"163","author":"M Tampaki","year":"2025","unstructured":"Tampaki, M., Tsochatzis, E., Lekakis, V. & Cholongitas, E. Prevalence, characteristics and outcomes of patients with metabolic and alcohol related\/associated liver disease (MetALD): a systematic review and meta-analysis. Metabolism 163, 156101 (2025).","journal-title":"Metabolism"},{"key":"1219_CR22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2468-1253(24)00427-8","volume":"10","author":"A Krag","year":"2025","unstructured":"Krag, A., Torp, N., Younossi, Z. M. & Israelsen, M. Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD. Lancet Gastroenterol. Hepatol. 10, 282\u2013284 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1219_CR23","doi-asserted-by":"publisher","first-page":"100706","DOI":"10.1016\/j.aohep.2022.100706","volume":"27","author":"YAO Rojas","year":"2022","unstructured":"Rojas, Y. A. O., Cuellar, C. L. V., Barr\u00f3n, K. M. A., Arab, J. P. & Miranda, A. L. Non-alcoholic fatty liver disease prevalence in Latin America: a systematic review and meta-analysis. Ann. Hepatol. 27, 100706 (2022).","journal-title":"Ann. Hepatol."},{"key":"1219_CR24","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1016\/j.jhep.2023.08.025","volume":"80","author":"H Perazzo","year":"2024","unstructured":"Perazzo, H., Pacheco, A. G., Griep, R. H. & Collaborators. Changing from NAFLD through MAFLD to MASLD: similar prevalence and risk factors in a large Brazilian cohort. J. Hepatol. 80, e72\u2013e74 (2024).","journal-title":"J. Hepatol."},{"key":"1219_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4067\/s0034-98872024000200187","volume":"152","author":"J P\u00e9rez-Valenzuela","year":"2024","unstructured":"P\u00e9rez-Valenzuela, J., Aguirre, H., Mart\u00ednez, L., Castro, L. & Mezzano, G. Prevalence and clinical associations of steatotic liver disease in a Preventive Medicine Unit: a cross-sectional study. Rev. Med. Chil. 152, 187\u2013196 (2024).","journal-title":"Rev. Med. Chil."},{"key":"1219_CR26","doi-asserted-by":"publisher","first-page":"101919","DOI":"10.1016\/j.aohep.2025.101919","volume":"30","author":"M Spencer-Sandino","year":"2025","unstructured":"Spencer-Sandino, M. et al. New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile. Ann. Hepatol. 30, 101919 (2025).","journal-title":"Ann. Hepatol."},{"key":"1219_CR27","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1017\/S0007114523000028","volume":"130","author":"P Pettinelli","year":"2023","unstructured":"Pettinelli, P. et al. Prevalence of non-alcoholic fatty liver disease and its association with lifestyle habits in adults in Chile: a cross-sectional study from the National Health Survey 2016-2017. Br. J. Nutr. 130, 1036\u20131046 (2023).","journal-title":"Br. J. Nutr."},{"key":"1219_CR28","doi-asserted-by":"publisher","first-page":"102149","DOI":"10.1016\/j.aohep.2025.102149","volume":"31","author":"JE Lira-Vera","year":"2025","unstructured":"Lira-Vera, J. E. et al. Assessment of metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, and metabolic dysfunction and alcohol-associated steatotic liver disease in open Mexican population. Ann. Hepatol. 31, 102149 (2025).","journal-title":"Ann. Hepatol."},{"key":"1219_CR29","doi-asserted-by":"publisher","first-page":"102186","DOI":"10.1016\/j.aohep.2026.102186","volume":"31","author":"JE Prieto","year":"2026","unstructured":"Prieto, J. E. et al. Clinical, etiological, and demographic aspects of cirrhosis in South America: a report from the South American liver research network. Ann. Hepatol. 31, 102186 (2026).","journal-title":"Ann. Hepatol."},{"key":"1219_CR30","doi-asserted-by":"publisher","first-page":"103240","DOI":"10.1016\/j.arcmed.2025.103240","volume":"56","author":"N M\u00e9ndez-S\u00e1nchez","year":"2025","unstructured":"M\u00e9ndez-S\u00e1nchez, N. et al. Changing landscape of liver cirrhosis etiologies. Arch. Med. Res. 56, 103240 (2025).","journal-title":"Arch. Med. Res."},{"key":"1219_CR31","first-page":"100151","volume":"7","author":"A Gonzalez-Chagolla","year":"2022","unstructured":"Gonzalez-Chagolla, A. et al. Cirrhosis etiology trends in developing countries: transition from infectious to metabolic conditions. Report from a multicentric cohort in central Mexico. Lancet Reg. Health Am. 7, 100151 (2022).","journal-title":"Lancet Reg. Health Am."},{"key":"1219_CR32","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/S0140-6736(25)01637-X","volume":"406","author":"GBD 2023 Disease and Injury and Risk Factor Collaborators.","year":"2025","unstructured":"GBD 2023 Disease and Injury and Risk Factor Collaborators. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the global burden of disease study 2023. Lancet 406, 1873\u20131922 (2025).","journal-title":"Lancet"},{"key":"1219_CR33","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41569-024-01058-2","volume":"21","author":"LCC Brant","year":"2024","unstructured":"Brant, L. C. C. et al. Epidemiology of cardiometabolic health in Latin America and strategies to address disparities. Nat. Rev. Cardiol. 21, 849\u2013864 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"1219_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/cld.1025","volume":"16","author":"LA D\u00edaz","year":"2020","unstructured":"D\u00edaz, L. A., Roblero, J. P., Bataller, R. & Arab, J. P. Alcohol-related liver disease in Latin America: local solutions for a global problem. Clin. Liver Dis. 16, 187\u2013190 (2020).","journal-title":"Clin. Liver Dis."},{"key":"1219_CR35","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/apt.17615","volume":"58","author":"JA Akambase","year":"2023","unstructured":"Akambase, J. A. et al. Epidemiology and risk factors for histopathologic characteristics of non-alcoholic fatty liver disease in South America. Aliment. Pharmacol. Ther. 58, 526\u2013536 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1219_CR36","doi-asserted-by":"publisher","first-page":"101903","DOI":"10.1016\/j.aohep.2025.101903","volume":"30","author":"LA Diaz","year":"2025","unstructured":"Diaz, L. A. et al. Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group. Ann. Hepatol. 30, 101903 (2025).","journal-title":"Ann. Hepatol."},{"key":"1219_CR37","unstructured":"World Health Organization. Obesity and overweight. WHO https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (2025)."},{"key":"1219_CR38","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"GBD 2021 Adult BMI Collaborators.","year":"2025","unstructured":"GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 405, 813\u2013838 (2025).","journal-title":"Lancet"},{"key":"1219_CR39","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s42255-024-00977-1","volume":"6","author":"SRG Ferreira","year":"2024","unstructured":"Ferreira, S. R. G., Macotela, Y., Velloso, L. A. & Mori, M. A. Determinants of obesity in Latin America. Nat. Metab. 6, 409\u2013432 (2024).","journal-title":"Nat. Metab."},{"key":"1219_CR40","doi-asserted-by":"publisher","first-page":"1562060","DOI":"10.3389\/fendo.2025.1562060","volume":"16","author":"VJ Vera-Ponce","year":"2025","unstructured":"Vera-Ponce, V. J. et al. Abdominal obesity prevalence in Latin America: a systematic review and meta-analysis comparing ATP III and IDF criteria. Front. Endocrinol. 16, 1562060 (2025).","journal-title":"Front. Endocrinol."},{"key":"1219_CR41","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21149\/15863","volume":"22","author":"S Barquera","year":"2024","unstructured":"Barquera, S. et al. Obesidad en adultos. Salud Publica Mex. 22, 414\u2013424 (2024).","journal-title":"Salud Publica Mex."},{"key":"1219_CR42","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi, K. et al. Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention. A consensus report of the American Diabetes Association. Diabetes Care 48, 1057\u20131082 (2025).","journal-title":"Diabetes Care"},{"key":"1219_CR43","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S2213-8587(22)00186-3","volume":"10","author":"GBD 2019 Diabetes in the Americas Collaborators.","year":"2022","unstructured":"GBD 2019 Diabetes in the Americas Collaborators. Burden of diabetes and hyperglycaemia in adults in the Americas, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet Diabetes Endocrinol. 10, 655\u2013667 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1219_CR44","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.puhe.2024.05.009","volume":"233","author":"I Ilic","year":"2024","unstructured":"Ilic, I. & Ilic, M. The burden of type 2 diabetes mellitus in Latin America, 1990-2019: findings from the global burden of disease study. Public Health 233, 74\u201382 (2024).","journal-title":"Public Health"},{"key":"1219_CR45","unstructured":"International Diabetes Federation. South and Central America: diabetes regional report 2000\u20132050. Diabetes Atlas https:\/\/diabetesatlas.org\/data-by-location\/region\/south-and-central-america (2025)."},{"key":"1219_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"GBD 2021 Diabetes Collaborators.","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203\u2013234 (2023).","journal-title":"Lancet"},{"key":"1219_CR47","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","volume":"81","author":"D Marti-Aguado","year":"2024","unstructured":"Marti-Aguado, D. et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J. Hepatol. 81, 930\u2013940 (2024).","journal-title":"J. Hepatol."},{"key":"1219_CR48","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/apt.70335","volume":"62","author":"Y Lei","year":"2025","unstructured":"Lei, Y. et al. Review Article: Impact of alcohol consumption on the development and progression of metabolic dysfunction-associated steatotic liver disease. Aliment. Pharmacol. Ther. 62, 680\u2013691 (2025).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1219_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang, D. Q., Mathurin, P., Cortez-Pinto, H. & Loomba, R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat. Rev. Gastroenterol. Hepatol. 20, 37\u201349 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1219_CR50","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/dar.13286","volume":"40","author":"J Rehm","year":"2021","unstructured":"Rehm, J. et al. The role of alcohol use in the aetiology and progression of liver disease: a narrative review and a quantification. Drug Alcohol Rev. 40, 1377\u20131386 (2021).","journal-title":"Drug Alcohol Rev."},{"key":"1219_CR51","doi-asserted-by":"publisher","first-page":"e0192","DOI":"10.1097\/CLD.0000000000000192","volume":"23","author":"H Desalegn","year":"2024","unstructured":"Desalegn, H., Diaz, L. A., Rehm, J. & Arab, J. P. Impact of alcohol use on liver disease outcomes. Clin. Liver Dis. 23, e0192 (2024).","journal-title":"Clin. Liver Dis."},{"key":"1219_CR52","unstructured":"World Health Organization. Global Status Report on Alcohol and Health and Treatment of Substance Use Disorders (WHO, 2024)."},{"key":"1219_CR53","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/apt.70256","volume":"62","author":"M Kubina","year":"2025","unstructured":"Kubina, M. et al. Meta-Analysis: effects of steatotic liver disease-associated genetic risk alleles on longitudinal outcomes. Aliment. Pharmacol. Ther. 62, 244\u2013276 (2025).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1219_CR54","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1016\/j.cgh.2024.05.052","volume":"22","author":"S Sookoian","year":"2024","unstructured":"Sookoian, S., Rotman, Y. & Valenti, L. Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update. Clin. Gastroenterol. Hepatol. 22, 2177\u20132187.e3 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1219_CR55","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1055\/a-2630-0952","volume":"45","author":"M Israelsen","year":"2025","unstructured":"Israelsen, M., Tr\u00e9po, E., Krag, A. & Stender, S. MetALD: genetic factors and clinical outcomes. Semin. Liver Dis. 45, 269\u2013282 (2025).","journal-title":"Semin. Liver Dis."},{"key":"1219_CR56","doi-asserted-by":"publisher","first-page":"e70240","DOI":"10.1111\/liv.70240","volume":"45","author":"S Romeo","year":"2025","unstructured":"Romeo, S. & Valenti, L. Fifteen years of PNPLA3: transforming hepatology through human genetics. Liver Int. 45, e70240 (2025).","journal-title":"Liver Int."},{"key":"1219_CR57","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jhep.2014.02.030","volume":"61","author":"Y-L Liu","year":"2014","unstructured":"Liu, Y.-L. et al. Carriage of the PNPLA3 rs738409 C>G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J. Hepatol. 61, 75\u201381 (2014).","journal-title":"J. Hepatol."},{"key":"1219_CR58","doi-asserted-by":"publisher","first-page":"e16123","DOI":"10.1111\/liv.16123","volume":"45","author":"J Kozlitina","year":"2025","unstructured":"Kozlitina, J. & Sookoian, S. Global epidemiological impact of PNPLA3 I148M on liver disease. Liver Int. 45, e16123 (2025).","journal-title":"Liver Int."},{"key":"1219_CR59","doi-asserted-by":"publisher","first-page":"e2234221","DOI":"10.1001\/jamanetworkopen.2022.34221","volume":"5","author":"H-S Kim","year":"2022","unstructured":"Kim, H.-S. et al. Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality. JAMA Netw. Open 5, e2234221 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1219_CR60","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/ng.3855","volume":"49","author":"S Stender","year":"2017","unstructured":"Stender, S. et al. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat. Genet. 49, 842\u2013847 (2017).","journal-title":"Nat. Genet."},{"key":"1219_CR61","doi-asserted-by":"publisher","first-page":"e16211","DOI":"10.1111\/liv.16211","volume":"45","author":"C Galvanin","year":"2025","unstructured":"Galvanin, C., Buch, S., Nahon, P. & Tr\u00e9po, E. PNPLA3 in alcohol-related liver disease. Liver Int. 45, e16211 (2025).","journal-title":"Liver Int."},{"key":"1219_CR62","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/hep.27556","volume":"61","author":"S Sookoian","year":"2015","unstructured":"Sookoian, S. et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 61, 515\u2013525 (2015).","journal-title":"Hepatology"},{"key":"1219_CR63","doi-asserted-by":"publisher","first-page":"e87523","DOI":"10.1371\/journal.pone.0087523","volume":"9","author":"S Petta","year":"2014","unstructured":"Petta, S. et al. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS ONE\u00a09, e87523 (2014).","journal-title":"PLoS ONE"},{"key":"1219_CR64","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","volume":"378","author":"NS Abul-Husn","year":"2018","unstructured":"Abul-Husn, N. S. et al. A protein-truncating HSD17B13 variant and protection from chronic liver disease. N. Engl. J. Med. 378, 1096\u20131106 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1219_CR65","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/apt.17292","volume":"57","author":"M Amangurbanova","year":"2023","unstructured":"Amangurbanova, M., Huang, D. Q. & Loomba, R. Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD. Aliment. Pharmacol. Ther. 57, 37\u201351 (2023).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1219_CR66","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.mce.2018.10.014","volume":"489","author":"W Su","year":"2019","unstructured":"Su, W. et al. Role of HSD17B13 in the liver physiology and pathophysiology. Mol. Cell Endocrinol. 489, 119\u2013125 (2019).","journal-title":"Mol. Cell Endocrinol."},{"key":"1219_CR67","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nature15394","volume":"526","author":"PH Sudmant","year":"2015","unstructured":"Sudmant, P. H. et al. An integrated map of structural variation in 2,504 human genomes. Nature 526, 75\u201381 (2015).","journal-title":"Nature"},{"key":"1219_CR68","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-023-06045-0","volume":"625","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. A genomic mutational constraint map using variation in 76,156 human genomes. Nature 625, 92\u2013100 (2024).","journal-title":"Nature"},{"key":"1219_CR69","doi-asserted-by":"publisher","first-page":"100728","DOI":"10.1016\/j.aohep.2022.100728","volume":"27","author":"LN Cavalcante","year":"2022","unstructured":"Cavalcante, L. N. et al. African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population. Ann. Hepatol. 27, 100728 (2022).","journal-title":"Ann. Hepatol."},{"key":"1219_CR70","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.ajhg.2023.08.015","volume":"110","author":"SG Medina-Mu\u00f1oz","year":"2023","unstructured":"Medina-Mu\u00f1oz, S. G. et al. Demographic modeling of admixed Latin American populations from whole genomes. Am. J. Hum. Genet. 110, 1804\u20131816 (2023).","journal-title":"Am. J. Hum. Genet."},{"key":"1219_CR71","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/oby.22527","volume":"27","author":"KA Young","year":"2019","unstructured":"Young, K. A. et al. Genome-wide association study identifies loci for liver enzyme concentrations in Mexican Americans: the Guardian Consortium. Obesity 27, 1331\u20131337 (2019).","journal-title":"Obesity"},{"key":"1219_CR72","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000520734","volume":"86","author":"JD Roe","year":"2021","unstructured":"Roe, J. D., Garcia, L. A., Klimentidis, Y. C. & Coletta, D. K. Association of PNPLA3 I148M with liver disease biomarkers in Latinos. Hum. Hered. 86, 21\u201327 (2021).","journal-title":"Hum. Hered."},{"key":"1219_CR73","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.cgh.2022.12.025","volume":"21","author":"SM Rutledge","year":"2023","unstructured":"Rutledge, S. M. et al. Association of HSD17B13 and PNPLA3 with liver enzymes and fibrosis in Hispanic\/Latino individuals of diverse genetic ancestries. Clin. Gastroenterol. Hepatol. 21, 2578\u20132587.e11 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1219_CR74","doi-asserted-by":"publisher","first-page":"792","DOI":"10.4254\/wjh.v12.i10.792","volume":"12","author":"QC Lisboa","year":"2020","unstructured":"Lisboa, Q. C. et al. and polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J. Hepatol. 12, 792\u2013806 (2020).","journal-title":"World J. Hepatol."},{"key":"1219_CR75","doi-asserted-by":"publisher","first-page":"250","DOI":"10.5604\/01.3001.0010.8644","volume":"17","author":"P Chinchilla-L\u00f3pez","year":"2018","unstructured":"Chinchilla-L\u00f3pez, P. et al. More evidence for the genetic susceptibility of Mexican population to nonalcoholic fatty liver disease through PNPLA3. Ann. Hepatol. 17, 250\u2013255 (2018).","journal-title":"Ann. Hepatol."},{"key":"1219_CR76","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1194\/jlr.P900013-JLR200","volume":"50","author":"S Sookoian","year":"2009","unstructured":"Sookoian, S. et al. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J. Lipid Res. 50, 2111\u20132116 (2009).","journal-title":"J. Lipid Res."},{"key":"1219_CR77","doi-asserted-by":"publisher","first-page":"6406","DOI":"10.3390\/ijms26136406","volume":"26","author":"S Rocha","year":"2025","unstructured":"Rocha, S. et al. Polymorphism\u2019s MBOAT7 as risk and MTARC1 as protection for liver fibrosis in MASLD. Int. J. Mol. Sci. 26, 6406 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"1219_CR78","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/liv.15845","volume":"44","author":"NC Lavrado","year":"2024","unstructured":"Lavrado, N. C. et al. Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus. Liver Int. 44, 1042\u20131050 (2024).","journal-title":"Liver Int."},{"key":"1219_CR79","doi-asserted-by":"publisher","first-page":"e186424","DOI":"10.1172\/JCI186424","volume":"135","author":"VL Chen","year":"2025","unstructured":"Chen, V. L. et al. Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment. J. Clin. Invest. 135, e186424 (2025).","journal-title":"J. Clin. Invest."},{"key":"1219_CR80","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.cgh.2020.11.038","volume":"20","author":"M Israelsen","year":"2022","unstructured":"Israelsen, M. et al. Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis. Clin. Gastroenterol. Hepatol. 20, 1784\u20131794.e9 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1219_CR81","doi-asserted-by":"publisher","DOI":"10.20517\/mtod.2023.45","volume":"4","author":"R Gulati","year":"2024","unstructured":"Gulati, R., Moylan, C. A., Wilder, J. & Wegermann, K. Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease. Metab. Target Organ Damage 4, 9 (2024).","journal-title":"Metab. Target Organ Damage"},{"key":"1219_CR82","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","volume":"73","author":"G Targher","year":"2024","unstructured":"Targher, G., Byrne, C. D. & Tilg, H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73, 691\u2013702 (2024).","journal-title":"Gut"},{"key":"1219_CR83","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams, L. A., Anstee, Q. M., Tilg, H. & Targher, G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66, 1138\u20131153 (2017).","journal-title":"Gut"},{"key":"1219_CR84","first-page":"e168","volume":"42","author":"PB Duell","year":"2022","unstructured":"Duell, P. B. et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association Arterioscler Thromb Vasc Biol. Am. Heart Assoc. Arterioscler. Thromb. Vasc. Biol. 42, e168\u2013e185 (2022).","journal-title":"Am. Heart Assoc. Arterioscler. Thromb. Vasc. Biol."},{"key":"1219_CR85","first-page":"e563","volume":"140","author":"DK Arnett","year":"2019","unstructured":"Arnett, D. K. et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation 140, e563\u2013e595 (2019).","journal-title":"Circulation"},{"key":"1219_CR86","doi-asserted-by":"publisher","first-page":"710","DOI":"10.14309\/ajg.0000000000003595","volume":"121","author":"AS Barritt 4th","year":"2026","unstructured":"Barritt, A. S. 4th et al. Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease. Am. J. Gastroenterol.  121, 710\u2013719\u00a0(2026).","journal-title":"Am. J. Gastroenterol."},{"key":"1219_CR87","doi-asserted-by":"publisher","first-page":"133143","DOI":"10.1016\/j.ijcard.2025.133143","volume":"428","author":"L Alhuneafat","year":"2025","unstructured":"Alhuneafat, L. et al. The burden of cardiovascular disease in Latin America and the Caribbean, 1990-2019: an analysis of the Global Burden of Disease Study. Int. J. Cardiol. 428, 133143 (2025).","journal-title":"Int. J. Cardiol."},{"key":"1219_CR88","first-page":"100960","volume":"42","author":"P Joseph","year":"2025","unstructured":"Joseph, P. et al. Cardiovascular disease in the Americas: the epidemiology of cardiovascular disease and its risk factors. Lancet Reg. Health Am. 42, 100960 (2025).","journal-title":"Lancet Reg. Health Am."},{"key":"1219_CR89","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/dom.16186","volume":"27","author":"Y Peng","year":"2025","unstructured":"Peng, Y. et al. Metabolic dysfunction-associated steatotic liver disease and cancer risk: a cohort study. Diabetes Obes. Metab. 27, 1940\u20131949 (2025).","journal-title":"Diabetes Obes. Metab."},{"key":"1219_CR90","doi-asserted-by":"publisher","first-page":"156014","DOI":"10.1016\/j.metabol.2024.156014","volume":"160","author":"A Mantovani","year":"2024","unstructured":"Mantovani, A., Lonardo, A., Stefan, N. & Targher, G. Metabolic dysfunction-associated steatotic liver disease and extrahepatic gastrointestinal cancers. Metabolism 160, 156014 (2024).","journal-title":"Metabolism"},{"key":"1219_CR91","doi-asserted-by":"publisher","first-page":"e0289675","DOI":"10.1371\/journal.pone.0289675","volume":"18","author":"CD Muzi","year":"2023","unstructured":"Muzi, C. D., Banegas, M. P. & Guimar\u00e3es, R. M. Colorectal cancer disparities in Latin America: mortality trends 1990-2019 and a paradox association with human development. PLoS ONE\u00a018, e0289675 (2023).","journal-title":"PLoS ONE"},{"key":"1219_CR92","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(24)00600-4","volume":"26","author":"H Sung","year":"2025","unstructured":"Sung, H. et al. Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data. Lancet Oncol. 26, 51\u201363 (2025).","journal-title":"Lancet Oncol."},{"key":"1219_CR93","first-page":"101147","volume":"48","author":"G Gomez-Abuin","year":"2025","unstructured":"Gomez-Abuin, G., Mand\u00f3, P., Curigliano, G. & Barrios, C. H. Main challenges to cancer care in Latin America: an analysis through breast cancer lenses. Lancet Reg. Health Am. 48, 101147 (2025).","journal-title":"Lancet Reg. Health Am."},{"key":"1219_CR94","doi-asserted-by":"publisher","first-page":"156004","DOI":"10.1016\/j.metabol.2024.156004","volume":"160","author":"M Kalligeros","year":"2024","unstructured":"Kalligeros, M., Henry, L. & Younossi, Z. M. Metabolic dysfunction-associated steatotic liver disease and its link to cancer. Metabolism 160, 156004 (2024).","journal-title":"Metabolism"},{"key":"1219_CR95","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1111\/apt.18286","volume":"60","author":"Y Park","year":"2024","unstructured":"Park, Y., Jung, J., Han, S. & Kim, G.-A. Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: a nationwide cohort study. Aliment. Pharmacol. Ther. 60, 1599\u20131608\u00a0(2024).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1219_CR96","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.jhepr.2024.101250","volume":"7","author":"J Gratac\u00f3s-Gin\u00e8s","year":"2025","unstructured":"Gratac\u00f3s-Gin\u00e8s, J., Ari\u00f1o, S., Sancho-Bru, P., Bataller, R. & Pose, E. MetALD: clinical aspects, pathophysiology and treatment. JHEP Rep. 7, 101250 (2025).","journal-title":"JHEP Rep."},{"key":"1219_CR97","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2468-1253(23)00206-6","volume":"8","author":"M Israelsen","year":"2023","unstructured":"Israelsen, M., Torp, N., Johansen, S., Thiele, M. & Krag, A. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. Lancet Gastroenterol. Hepatol. 8, 866\u2013868 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1219_CR98","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cgh.2025.02.017","volume":"24","author":"LA Diaz","year":"2025","unstructured":"Diaz, L. A. et al. An expert consensus Delphi panel in MetALD: opportunities and challenges in clinical practice. Clin. Gastroenterol. Hepatol. 24, 633\u2013645.e4\u00a0(2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1219_CR99","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cgh.2023.11.003","volume":"22","author":"M Kalligeros","year":"2023","unstructured":"Kalligeros, M. et al. Prevalence of steatotic liver disease (MASLD, MetALD and ALD) in the United States: NHANES 2017-2020. Clin. Gastroenterol. Hepatol. 22, 1330-1332.e4\u00a0(2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1219_CR100","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/HEP.0000000000000664","volume":"79","author":"C-M Lee","year":"2024","unstructured":"Lee, C.-M. et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology  79, 1393\u20131400 (2024).","journal-title":"Hepatology"},{"key":"1219_CR101","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/apt.17958","volume":"59","author":"CV Schneider","year":"2024","unstructured":"Schneider, C. V. et al. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population. Aliment. Pharmacol. Ther. 59, 1271\u20131281 (2024).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1219_CR102","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2468-1253(24)00380-7","volume":"10","author":"LA D\u00edaz","year":"2025","unstructured":"D\u00edaz, L. A. et al. Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective. Lancet Gastroenterol. Hepatol. 10, 475\u2013490 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1219_CR103","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cgh.2025.07.022","volume":"24","author":"SE Congly","year":"2025","unstructured":"Congly, S. E. et al. Phosphatidylethanol is cost-effective to accurately detect periodic alcohol use in patients with alcohol-associated liver disease. Clin. Gastroenterol. Hepatol. 24, 569\u2013571\u00a0(2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1219_CR104","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1053\/j.gastro.2025.07.007","volume":"169","author":"R Loomba","year":"2025","unstructured":"Loomba, R., Hagstr\u00f6m, H. & D\u00edaz, L. A. Emerging role of phosphatidylethanol testing in clinical practice for the identification of steatotic liver disease subtypes: is this the new standard. Gastroenterology 169, 1103\u20131107\u00a0(2025).","journal-title":"Gastroenterology"},{"key":"1219_CR105","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.jhep.2025.04.019","volume":"83","author":"J Vaz","year":"2025","unstructured":"Vaz, J. et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J. Hepatol. 83, 1011\u20131022\u00a0(2025).","journal-title":"J. Hepatol."},{"key":"1219_CR106","doi-asserted-by":"publisher","first-page":"101200","DOI":"10.1016\/j.jhepr.2024.101200","volume":"7","author":"ED Hansen","year":"2025","unstructured":"Hansen, E. D. et al. Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake. JHEP Rep. 7, 101200 (2025).","journal-title":"JHEP Rep."},{"key":"1219_CR107","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jhep.2025.05.030","volume":"83","author":"F Tavaglione","year":"2025","unstructured":"Tavaglione, F. et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J. Hepatol. 83, 1023\u20131034\u00a0(2025).","journal-title":"J. Hepatol."},{"key":"1219_CR108","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/j.jhep.2025.06.026","volume":"83","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M., Zelber-Sagi, S. & Krag, A. Reframing the spectrum of steatotic liver disease as a dynamic concept. J. Hepatol. 83, e191\u2013e193 (2025).","journal-title":"J. Hepatol."},{"key":"1219_CR109","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/HEP.0000000000000925","volume":"81","author":"M Kwak","year":"2025","unstructured":"Kwak, M. et al. MASLD\/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population based study with 26.7 years of follow-up. Hepatology 81, 228\u2013237\u00a0(2025).","journal-title":"Hepatology"},{"key":"1219_CR110","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/liv.15939","volume":"44","author":"S Ciardullo","year":"2024","unstructured":"Ciardullo, S. et al. Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence. Liver Int. 44, 1762\u20131767 (2024).","journal-title":"Liver Int."},{"key":"1219_CR111","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/HEP.0000000000000914","volume":"81","author":"P Ochoa-Allemant","year":"2025","unstructured":"Ochoa-Allemant, P. et al. Waitlisting and liver transplantation for MetALD in the United States: an analysis of the UNOS national registry. Hepatology 81, 532\u2013545\u00a0(2025).","journal-title":"Hepatology"},{"key":"1219_CR112","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.transproceed.2017.11.072","volume":"50","author":"L Haddad","year":"2018","unstructured":"Haddad, L. et al. Characteristics of liver transplantation in Argentina: a multicenter study. Transplant. Proc. 50, 478\u2013484 (2018).","journal-title":"Transplant. Proc."},{"key":"1219_CR113","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.transproceed.2017.11.046","volume":"50","author":"LA Caicedo","year":"2018","unstructured":"Caicedo, L. A. et al. Liver transplantation in hepatitis C-infected patients: experience from a south American transplant center. Transplant. Proc. 50, 493\u2013498 (2018).","journal-title":"Transplant. Proc."},{"key":"1219_CR114","first-page":"100633","volume":"28","author":"D Aguirre-Villarreal","year":"2023","unstructured":"Aguirre-Villarreal, D. et al. Liver transplantation in Latin America: reality and challenges. Lancet Reg. Health Am. 28, 100633 (2023).","journal-title":"Lancet Reg. Health Am."},{"key":"1219_CR115","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s00423-023-03144-4","volume":"408","author":"AL Hill","year":"2023","unstructured":"Hill, A. L. et al. Global liver transplantation: emerging trends and ethical challenges. Langenbecks Arch. Surg. 408, 418 (2023).","journal-title":"Langenbecks Arch. Surg."},{"key":"1219_CR116","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2468-1253(20)30340-X","volume":"6","author":"N Mendez-Sanchez","year":"2021","unstructured":"Mendez-Sanchez, N. et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol. Hepatol. 6, 65\u201372 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1219_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s44355-024-00014-8","volume":"2","author":"H Leal-Lassalle","year":"2025","unstructured":"Leal-Lassalle, H., Est\u00e9vez-V\u00e1zquez, O., Cubero, F. J. & Nevzorova, Y. A. Metabolic and alcohol-associated liver disease (MetALD): a representation of duality. npj Gut Liver 2, 1 (2025).","journal-title":"npj Gut Liver"},{"key":"1219_CR118","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/s41575-023-00822-y","volume":"20","author":"LA D\u00edaz","year":"2023","unstructured":"D\u00edaz, L. A., Arab, J. P., Louvet, A., Bataller, R. & Arrese, M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 20, 764\u2013783 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1219_CR119","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1097\/HEP.0000000000000935","volume":"80","author":"GW Marek","year":"2024","unstructured":"Marek, G. W. & Malhi, H. MetALD: does it require a different therapeutic option. Hepatology  80, 1424\u20131440\u00a0(2024).","journal-title":"Hepatology"},{"key":"1219_CR120","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jhep.2023.01.024","volume":"78","author":"E Lee","year":"2023","unstructured":"Lee, E., Korf, H. & Vidal-Puig, A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. J. Hepatol. 78, 1048\u20131062 (2023).","journal-title":"J. Hepatol."},{"key":"1219_CR121","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1440-1746.2011.07023.x","volume":"27","author":"S de la Monte","year":"2012","unstructured":"de la Monte, S., Derdak, Z. & Wands, J. R. Alcohol, insulin resistance and the liver-brain axis. J. Gastroenterol. Hepatol. 27, 33\u201341 (2012).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1219_CR122","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.jceh.2022.02.001","volume":"12","author":"G Ayares","year":"2022","unstructured":"Ayares, G., Idalsoaga, F., D\u00edaz, L. A., Arnold, J. & Arab, J. P. Current medical treatment for alcohol-associated liver disease. J. Clin. Exp. Hepatol.  12, 1333\u20131348\u00a0(2022).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"1219_CR123","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/jhep.2003.50346","volume":"38","author":"C-T Wai","year":"2003","unstructured":"Wai, C.-T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38, 518\u2013526 (2003).","journal-title":"Hepatology"},{"key":"1219_CR124","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43, 1317\u20131325 (2006).","journal-title":"Hepatology"},{"key":"1219_CR125","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1056\/NEJMra2403308","volume":"393","author":"L Castera","year":"2025","unstructured":"Castera, L., Rinella, M. E. & Tsochatzis, E. A. Noninvasive assessment of liver fibrosis. N. Engl. J. Med. 393, 1715\u20131729 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1219_CR126","doi-asserted-by":"publisher","first-page":"e0678","DOI":"10.1097\/HC9.0000000000000678","volume":"9","author":"AM Allen","year":"2025","unstructured":"Allen, A. M. et al. Global patterns of utilization of noninvasive tests for the clinical management of metabolic dysfunction-associated steatotic liver disease. Hepatol. Commun. 9, e0678 (2025).","journal-title":"Hepatol. Commun."},{"key":"1219_CR127","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001400","author":"LA Adams","year":"2025","unstructured":"Adams, L. A., Thiele, M. & Tsochatzis, E. A. Detecting at-risk steatotic liver disease and liver fibrosis in the community. Hepatology https:\/\/doi.org\/10.1097\/HEP.0000000000001400 (2025).","journal-title":"Hepatology"},{"key":"1219_CR128","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/acer.70114","volume":"49","author":"JC Kane","year":"2025","unstructured":"Kane, J. C. et al. Measuring alcohol consumption with biomarkers in intervention studies: a scoping review. Alcohol Clin. Exp. Res. 49, 1843\u20131854 (2025).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"1219_CR129","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.3390\/foods14122065","volume":"14","author":"S Parra-Soto","year":"2025","unstructured":"Parra-Soto, S. et al. Dietary patterns and sustainable lifestyles: a multicenter study from Latin America and Spain. Foods 14, 2065 (2025).","journal-title":"Foods"},{"key":"1219_CR130","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-016-2765-y","volume":"16","author":"M Fisberg","year":"2016","unstructured":"Fisberg, M. et al. Latin American Study of Nutrition and Health (ELANS): rationale and study design. BMC Public Health 16, 93 (2016).","journal-title":"BMC Public Health"},{"key":"1219_CR131","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/nu10040389","volume":"10","author":"M Fisberg","year":"2018","unstructured":"Fisberg, M. et al. Total and added sugar intake: assessment in eight Latin American countries. Nutrients 10, 389 (2018).","journal-title":"Nutrients"},{"key":"1219_CR132","doi-asserted-by":"publisher","first-page":"680452","DOI":"10.3389\/fnut.2021.680452","volume":"8","author":"C Figueroa","year":"2021","unstructured":"Figueroa, C. et al. Introducing plant-based Mediterranean diet as a lifestyle medicine approach in Latin America: opportunities within the Chilean context. Front. Nutr. 8, 680452 (2021).","journal-title":"Front. Nutr."},{"key":"1219_CR133","doi-asserted-by":"publisher","first-page":"e1232","DOI":"10.1016\/S2214-109X(24)00150-5","volume":"12","author":"T Strain","year":"2024","unstructured":"Strain, T. et al. National, regional, and global trends in insufficient physical activity among adults from 2000 to 2022: a pooled analysis of 507 population-based surveys with 5\u00b77 million participants. Lancet Glob. Health 12, e1232\u2013e1243 (2024).","journal-title":"Lancet Glob. Health"},{"key":"1219_CR134","doi-asserted-by":"publisher","first-page":"1605125","DOI":"10.3389\/ijph.2022.1605125","volume":"67","author":"AO Werneck","year":"2022","unstructured":"Werneck, A. O., Barboza, L. L., Silva, E. C. M. & Araujo, R. H. O. Sociodemographic Inequalities in Physical Activity in Latin America: time for policies targeted at groups that need it the most. Int. J. Public Health 67, 1605125 (2022).","journal-title":"Int. J. Public Health"},{"key":"1219_CR135","doi-asserted-by":"publisher","first-page":"1646147","DOI":"10.3389\/fpubh.2025.1646147","volume":"13","author":"LF Rojas-Araya","year":"2025","unstructured":"Rojas-Araya, L. F. et al. Alarming low adherence to the 24-hour movement behavior in adolescents \u2014 the Cogni-Action Project. Front. Public Health 13, 1646147 (2025).","journal-title":"Front. Public Health"},{"key":"1219_CR136","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1123\/jpah.2022-0305","volume":"20","author":"AO Werneck","year":"2023","unstructured":"Werneck, A. O. et al. Physical activity and sitting time patterns and sociodemographic correlates among 155,790 South American adults. J. Phys. Act. Health 20, 716\u2013726 (2023).","journal-title":"J. Phys. Act. Health"},{"key":"1219_CR137","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S2352-4642(19)30323-2","volume":"4","author":"R Guthold","year":"2020","unstructured":"Guthold, R., Stevens, G. A., Riley, L. M. & Bull, F. C. Global trends in insufficient physical activity among adolescents: a pooled analysis of 298 population-based surveys with 1\u00b76 million participants. Lancet Child Adolesc. Health 4, 23\u201335 (2020).","journal-title":"Lancet Child Adolesc. Health"},{"key":"1219_CR138","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1093\/ije\/dyy033","volume":"47","author":"N Aguilar-Farias","year":"2018","unstructured":"Aguilar-Farias, N. et al. A regional vision of physical activity, sedentary behaviour and physical education in adolescents from Latin America and the Caribbean: results from 26 countries. Int. J. Epidemiol. 47, 976\u2013986 (2018).","journal-title":"Int. J. Epidemiol."},{"key":"1219_CR139","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.amepre.2012.10.026","volume":"44","author":"CM Hoehner","year":"2013","unstructured":"Hoehner, C. M. et al. Physical activity interventions in Latin America: expanding and classifying the evidence. Am. J. Prev. Med. 44, e31\u2013e40 (2013).","journal-title":"Am. J. Prev. Med."},{"key":"1219_CR140","doi-asserted-by":"publisher","DOI":"10.1186\/s12966-020-01022-6","volume":"17","author":"B Klepac Pogrmilovic","year":"2020","unstructured":"Klepac Pogrmilovic, B. et al. National physical activity and sedentary behaviour policies in 76 countries: availability, comprehensiveness, implementation, and effectiveness. Int. J. Behav. Nutr. Phys. Act. 17, 116 (2020).","journal-title":"Int. J. Behav. Nutr. Phys. Act."},{"key":"1219_CR141","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-021-01426-1","volume":"20","author":"AL Ruano","year":"2021","unstructured":"Ruano, A. L., Rodr\u00edguez, D., Rossi, P. G. & Maceira, D. Understanding inequities in health and health systems in Latin America and the Caribbean: a thematic series. Int. J. Equity Health 20, 94 (2021).","journal-title":"Int. J. Equity Health"},{"key":"1219_CR142","unstructured":"World Bank. World Bank open data. World Bank https:\/\/data.worldbank.org (2026)."},{"key":"1219_CR143","unstructured":"Organisation for Economic Co-operation and Development & World Bank. Health at a Glance: Latin America and the Caribbean 2023 (OECD, 2023)."},{"key":"1219_CR144","first-page":"e126","volume":"42","author":"E B\u00e1scolo","year":"2018","unstructured":"B\u00e1scolo, E., Houghton, N. & Riego, D. Types of health systems reforms in Latin America and results in health access and coverageL\u00f3gica da transforma\u00e7\u00e3o dos siste- mas de sa\u00fade na Am\u00e9rica Latina e resultados no acesso e cobertura de sa\u00fade [Spanish]. Rev. Panam. Salud Publica 42, e126 (2018).","journal-title":"Rev. Panam. Salud Publica"},{"key":"1219_CR145","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13690-022-00793-7","volume":"80","author":"RE Gilardino","year":"2022","unstructured":"Gilardino, R. E., Valanzasca, P. & Rifkin, S. B. Has Latin America achieved universal health coverage yet? Lessons from four countries. Arch. Public Health 80, 38 (2022).","journal-title":"Arch. Public Health"},{"key":"1219_CR146","unstructured":"Pan American Health Organization. Salud Universal en el Siglo XXI: 40 A\u00f1os de Alma-Ata. Informe de la Comisi\u00f3n de Alto Nivel (PAHO, 2019)."},{"key":"1219_CR147","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/S2214-109X(23)00488-6","volume":"12","author":"J Roberti","year":"2024","unstructured":"Roberti, J. et al. Inequalities in health system coverage and quality: a cross-sectional survey of four Latin American countries. Lancet Glob. Health 12, e145\u2013e155 (2024).","journal-title":"Lancet Glob. Health"},{"key":"1219_CR148","unstructured":"Comisi\u00f3n Econ\u00f3mica para Am\u00e9rica Latina y el Caribe. Los Pueblos Ind\u00edgenas en Am\u00e9rica Latina. Avances en el \u00faltimo decenio y retos pendientes para la garant\u00eda de sus derechos (CEPAL, 2014)."},{"key":"1219_CR149","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1053\/j.gastro.2023.05.033","volume":"165","author":"AQ Farias","year":"2023","unstructured":"Farias, A. Q. et al. Genetic ancestry, race, and severity of acutely decompensated cirrhosis in Latin America. Gastroenterology 165, 696\u2013716 (2023).","journal-title":"Gastroenterology"},{"key":"1219_CR150","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/hep.32743","volume":"77","author":"A Kardashian","year":"2023","unstructured":"Kardashian, A., Serper, M., Terrault, N. & Nephew, L. D. Health disparities in chronic liver disease. Hepatology 77, 1382\u20131403 (2023).","journal-title":"Hepatology"},{"key":"1219_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-025-02495-2","volume":"24","author":"M Garza","year":"2025","unstructured":"Garza, M. & Abascal Miguel, L. Health disparities among indigenous populations in Latin America: a scoping review. Int. J. Equity Health 24, 119 (2025).","journal-title":"Int. J. Equity Health"},{"key":"1219_CR152","doi-asserted-by":"publisher","first-page":"139357","DOI":"10.1016\/j.scitotenv.2020.139357","volume":"733","author":"L D\u00edaz de Le\u00f3n-Mart\u00ednez","year":"2020","unstructured":"D\u00edaz de Le\u00f3n-Mart\u00ednez, L., de la Sierra-de la Vega, L., Palacios-Ram\u00edrez, A., Rodriguez-Aguilar, M. & Flores-Ram\u00edrez, R. Critical review of social, environmental and health risk factors in the Mexican indigenous population and their capacity to respond to the COVID-19. Sci. Total. Environ. 733, 139357 (2020).","journal-title":"Sci. Total. Environ."},{"key":"1219_CR153","doi-asserted-by":"publisher","first-page":"e1456","DOI":"10.1016\/j.cgh.2021.06.048","volume":"20","author":"ZM Younossi","year":"2022","unstructured":"Younossi, Z. M. et al. A global survey of physicians knowledge about nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 20, e1456\u2013e1468 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1219_CR154","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/ueg2.12445","volume":"11","author":"S Driessen","year":"2023","unstructured":"Driessen, S. et al. A global survey of health care workers\u2019 awareness of non-alcoholic fatty liver disease: the AwareNASH survey. United European Gastroenterol. J. 11, 654\u2013662 (2023).","journal-title":"United European Gastroenterol. J."},{"key":"1219_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2026.102211","author":"P Coste","year":"2026","unstructured":"Coste, P. et al. The global academic hepatology capacity index (IGCAH): a multi-source assessment reveals profound inequities across Latin America. Ann. Hepatol. https:\/\/doi.org\/10.1016\/j.aohep.2026.102211 (2026).","journal-title":"Ann. Hepatol."},{"key":"1219_CR156","doi-asserted-by":"publisher","first-page":"100359","DOI":"10.1016\/j.aohep.2021.100359","volume":"24","author":"JP Arab","year":"2021","unstructured":"Arab, J. P. et al. NAFLD: challenges and opportunities to address the public health problem in Latin America. Ann. Hepatol. 24, 100359 (2021).","journal-title":"Ann. Hepatol."},{"key":"1219_CR157","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41575-025-01081-9","volume":"22","author":"M El-Kassas","year":"2025","unstructured":"El-Kassas, M. Bridging the gap: increasing MENA representation in MASLD clinical trials. Nat. Rev. Gastroenterol. Hepatol. 22, 457\u2013458 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1219_CR158","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","volume":"9","author":"R Loomba","year":"2024","unstructured":"Loomba, R. et al. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Gastroenterol. Hepatol. 9, 1090\u20131100 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1219_CR159","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1219_CR160","doi-asserted-by":"publisher","first-page":"101966","DOI":"10.1016\/j.aohep.2025.101966","volume":"30","author":"LA D\u00edaz Piga","year":"2025","unstructured":"D\u00edaz Piga, L. A. et al. Liver fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) in Latin America: interim results from the Stella study. Ann. Hepatol. 30, 101966 (2025).","journal-title":"Ann. Hepatol."},{"key":"1219_CR161","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/lt.24793","volume":"23","author":"M Mendizabal","year":"2017","unstructured":"Mendizabal, M. & Silva, M. O. Developing multicenter consortia in liver disease in Latin America: challenges and opportunities. Liver Transpl. 23, 1210\u20131215 (2017).","journal-title":"Liver Transpl."},{"key":"1219_CR162","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2468-1253(24)00220-6","volume":"9","author":"JV Lazarus","year":"2024","unstructured":"Lazarus, J. V. et al. Best buy interventions to address the burden of steatotic liver disease. Lancet Gastroenterol. Hepatol. 9, 975\u2013977 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1219_CR163","doi-asserted-by":"publisher","DOI":"10.1186\/s12966-023-01455-9","volume":"20","author":"D Hammond","year":"2023","unstructured":"Hammond, D. et al. Awareness, use and understanding of nutrition labels among children and youth from six countries: findings from the 2019 - 2020 International Food Policy Study. Int. J. Behav. Nutr. Phys. Act. 20, 55 (2023).","journal-title":"Int. J. Behav. Nutr. Phys. Act."},{"key":"1219_CR164","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S2468-1253(22)00008-5","volume":"7","author":"LA D\u00edaz","year":"2022","unstructured":"D\u00edaz, L. A. et al. The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. Lancet Gastroenterol. Hepatol. 7, 552\u2013559 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1219_CR165","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/hep.32016","volume":"74","author":"LA D\u00edaz","year":"2021","unstructured":"D\u00edaz, L. A. et al. Impact of public health policies on alcohol-associated liver disease in Latin America: an ecological multinational study. Hepatology 74, 2478\u20132490 (2021).","journal-title":"Hepatology"},{"key":"1219_CR166","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jhep.2023.11.021","volume":"80","author":"L Retat","year":"2024","unstructured":"Retat, L. et al. Preventing liver disease with policy measures to tackle alcohol consumption and obesity: the HEPAHEALTH II study. J. Hepatol. 80, 543\u2013552 (2024).","journal-title":"J. Hepatol."},{"key":"1219_CR167","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jhep.2023.11.006","volume":"80","author":"LA D\u00edaz","year":"2024","unstructured":"D\u00edaz, L. A. et al. Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes. J. Hepatol. 80, 409\u2013418 (2024).","journal-title":"J. Hepatol."},{"key":"1219_CR168","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.amepre.2020.07.003","volume":"60","author":"R An","year":"2021","unstructured":"An, R. et al. Impact of sugar-sweetened beverage warning labels on consumer behaviors: a systematic review and meta-analysis. Am. J. Prev. Med. 60, 115\u2013126 (2021).","journal-title":"Am. J. Prev. Med."},{"key":"1219_CR169","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/obr.12364","volume":"17","author":"M Cecchini","year":"2016","unstructured":"Cecchini, M. & Warin, L. Impact of food labelling systems on food choices and eating behaviours: a systematic review and meta-analysis of randomized studies. Obes. Rev. 17, 201\u2013210 (2016).","journal-title":"Obes. Rev."},{"key":"1219_CR170","doi-asserted-by":"publisher","first-page":"e1004463","DOI":"10.1371\/journal.pmed.1004463","volume":"21","author":"LS Taillie","year":"2024","unstructured":"Taillie, L. S. et al. Decreases in purchases of energy, sodium, sugar, and saturated fat 3 years after implementation of the Chilean food labeling and marketing law: an interrupted time series analysis. PLoS Med. 21, e1004463 (2024).","journal-title":"PLoS Med."},{"key":"1219_CR171","doi-asserted-by":"publisher","first-page":"100254","DOI":"10.1016\/j.advnut.2024.100254","volume":"15","author":"M Perry","year":"2024","unstructured":"Perry, M. et al. National policies to limit food marketing and competitive food sales in schools: a global scoping review. Adv. Nutr. 15, 100254 (2024).","journal-title":"Adv. Nutr."},{"key":"1219_CR172","doi-asserted-by":"publisher","first-page":"h6704","DOI":"10.1136\/bmj.h6704","volume":"352","author":"MA Colchero","year":"2016","unstructured":"Colchero, M. A., Popkin, B. M., Rivera, J. A. & Ng, S. W. Beverage purchases from stores in Mexico under the excise tax on sugar sweetened beverages: observational study. BMJ 352, h6704 (2016).","journal-title":"BMJ"},{"key":"1219_CR173","doi-asserted-by":"publisher","first-page":"e1002596","DOI":"10.1371\/journal.pmed.1002596","volume":"15","author":"R Nakamura","year":"2018","unstructured":"Nakamura, R. et al. Evaluating the 2014 sugar-sweetened beverage tax in Chile: an observational study in urban areas. PLoS Med. 15, e1002596 (2018).","journal-title":"PLoS Med."},{"key":"1219_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04215-7","volume":"23","author":"EM Cadena","year":"2025","unstructured":"Cadena, E. M., Gallo, I. & Soto, V. E. Reformulation of ultra-processed products in Colombia after the introduction of public health regulations. BMC Med. 23, 446 (2025).","journal-title":"BMC Med."},{"key":"1219_CR175","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/dar.13227","volume":"40","author":"ME Medina-Mora","year":"2021","unstructured":"Medina-Mora, M. E., Monteiro, M., Rafful, C. & Samano, I. Comprehensive analysis of alcohol policies in the Latin America and the Caribbean. Drug Alcohol Rev. 40, 385\u2013401 (2021).","journal-title":"Drug Alcohol Rev."},{"key":"1219_CR176","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/heapol\/czaf104","volume":"41","author":"I Val\u00e9rio","year":"2026","unstructured":"Val\u00e9rio, I. et al. Untangling the complex web of alcohol policy needs and potential solutions in Brazil: evidence from civil society and political stakeholders. Health Policy Plan.\u00a041, 365\u2013375\u00a0(2026).","journal-title":"Health Policy Plan."},{"key":"1219_CR177","doi-asserted-by":"publisher","first-page":"101366","DOI":"10.1016\/j.lanepe.2025.101366","volume":"54","author":"I Nedic","year":"2025","unstructured":"Nedic, I., Brennan, P. N., Isaacs, S. D., Thiele, M. & Lazarus, J. V. Global think-tank on steatotic liver disease 2025 meeting. Lancet Reg. Health Eur. 54, 101366 (2025).","journal-title":"Lancet Reg. Health Eur."},{"key":"1219_CR178","doi-asserted-by":"publisher","first-page":"e70311","DOI":"10.1111\/liv.70311","volume":"45","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M. et al. Managing MASLD through preventive hepatology: integrating policy reform, public health and personalised care. Liver Int. 45, e70311 (2025).","journal-title":"Liver Int."},{"key":"1219_CR179","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi, Z. M., Kalligeros, M. & Henry, L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin. Mol. Hepatol. 31, S32\u2013S50 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"1219_CR180","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s00535-013-0850-x","volume":"49","author":"H-L Tan","year":"2014","unstructured":"Tan, H.-L. et al. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. J. Gastroenterol. 49, 1056\u20131064 (2014).","journal-title":"J. Gastroenterol."},{"key":"1219_CR181","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.cgh.2013.02.011","volume":"11","author":"R Hernaez","year":"2013","unstructured":"Hernaez, R. et al. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin. Gastroenterol. Hepatol. 11, 1183\u20131190.e2 (2013).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1219_CR182","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1111\/add.15475","volume":"116","author":"BR Chrystoja","year":"2021","unstructured":"Chrystoja, B. R. et al. Mortality in the Americas from 2013 to 2015 resulting from diseases, conditions and injuries which are 100% alcohol-attributable. Addiction 116, 2685\u20132696 (2021).","journal-title":"Addiction"},{"key":"1219_CR183","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s10620-022-07706-2","volume":"68","author":"KB Islam","year":"2023","unstructured":"Islam, K. B., Brandman, D., Chu, J. N., Goldman, M. L. & Fox, R. K. Primary care providers and nonalcoholic fatty liver disease: a needs assessment survey. Dig. Dis. Sci. 68, 434\u2013438 (2023).","journal-title":"Dig. Dis. Sci."},{"key":"1219_CR184","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/S1665-2681(19)31317-1","volume":"12","author":"A Said","year":"2013","unstructured":"Said, A., Gagovic, V., Malecki, K., Givens, M. L. & Nieto, F. J. Primary care practitioners survey of non-alcoholic fatty liver disease. Ann. Hepatol. 12, 758\u2013765 (2013).","journal-title":"Ann. Hepatol."},{"key":"1219_CR185","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the Liver.","year":"2021","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2014 2021 update. J. Hepatol. 75, 659\u2013689 (2021).","journal-title":"J. Hepatol."},{"key":"1219_CR186","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","volume":"71","author":"A Srivastava","year":"2019","unstructured":"Srivastava, A. et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J. Hepatol. 71, 371\u2013378 (2019).","journal-title":"J. Hepatol."},{"key":"1219_CR187","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.1016\/j.cgh.2022.11.020","volume":"21","author":"PM Diaz","year":"2023","unstructured":"Diaz, P. M. et al. Underrepresentation of racial and ethnic minorities in high-impact cirrhosis clinical trials. Clin. Gastroenterol. Hepatol. 21, 3173\u20133175.e1 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01219-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01219-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01219-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:02:33Z","timestamp":1787659353000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01219-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":187,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1219"],"URL":"https:\/\/doi.org\/10.1038\/s41575-026-01219-3","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"22 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A. consults for Inventiva and AstraZeneca and has served as a speaker for Siemens. C.P.O. consults for NovoNordisk, Boehringer Ingelheim, Inventiva, AstraZeneca, Echosens, Samsung and Siemens and has served as a speaker for NovoNordisk and Boehringer Ingelheim. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}